• Home
  • ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.

Author List
Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C
Publication
Nature communications
Publication ID (Profile URL)
https://researcherprofiles.org/profile/366099377
Publication Year
2022
PubMed ID
36117191
Publication Title
Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nat Commun. 2022 09 19; 13(1):5478.